Floatz logo

Ebx-102

Acute Lymphoblastic Leukaemia

Imperial College LondonCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Acute Lymphoblastic Leukaemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

Ebx-102 is also rated in:

chronic myeloid leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
acute leukemia of ambiguous lineageDormant
CCC
Indicative ·
51 / 100
View asset →
chronic myelomonocytic leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →